With multiple approved products, the field of stem cell
therapies has gained substantial momentum over the last decade; several
innovator companies are currently progressing their proprietary therapy
candidates with cautious optimism. In fact, recent studies suggest that mesenchymal
stem cells have the potential to end the Coronavirus (COVID-19) pandemic.
Roots
Analysis is pleased to
announce the publication of its recent study, titled, “Global Stem Cells
Market:
Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous);
Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor);
Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere,
Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta,
Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.
The report features an extensive study of the
current market landscape, offering an informed opinion on the likely adoption
of these therapeutics over the next decade. The report features an in-depth analysis,
highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:
§ A
detailed assessment of the current market landscape of companies engaged in the
development of stem cell therapies for treatment of wide range of clinical
conditions
§ Elaborate
profiles of key industry players engaged in the development of stem cell
therapies (shortlisted on the basis of the product portfolio).
§ An
insightful competitiveness analysis featuring a four-dimensional bubble chart,
highlighting the key players in this domain.
§ An
assessment of over 20 commonly targeted therapeutic areas and details of stem
cell-based therapies being developed to treat the same conditions.
§ A
detailed proprietary 2×2 representation that was developed to assess the
current market scenario (in terms of existing competition and growth opportunities)
across emerging and established market segments.
§ An
in-depth analysis of more than 1,500 grants that have been awarded to research
institutes engaged in stem cell therapy-related projects, in the period between
2015 and 2019 (till November)
§ A
detailed clinical trial analysis on more than 540 completed, ongoing and
planned studies of various stem cell therapies, highlighting prevalent trends
across various relevant parameters.
§ A
review of the key aspects related to the manufacturing of stem cell therapies,
including [A] a detailed discussion on processes and protocols, highlighting
the need to outsource various aspects of stem cell therapy development and
manufacturing operations, [B] an assessment of the current market landscape of
contract manufacturers, providing information on stem cell-focused service
providers, and [C] an insightful Harvey ball analysis to identify the key
performance indicators / key considerations that industry stakeholders are
likely to take into consideration while selecting a suitable CMO / CRO partner.
§ A
detailed market gap analysis in order to develop a realistic understanding of
the demand and supply dynamics within this field, comparing both clinical and
commercial capabilities of therapy developers and the availability and
capabilities of contract manufacturers, across different geographies.
§ An
elaborate discussion on the various strategies that can be adopted by stem cell
therapy developers across different stages of product development and
commercialization.
§ A detailed market forecast, featuring analysis
of the current and projected future opportunity across key market segments
(listed below)
§ Source
of Stem Cell
§
Allogeneic
§
Autologous
§ Origin
of Stem Cell
§
Adult
§
Embryonic
§ Type
of Stem Cell
§ Hematopoietic
§ Mesenchymal
§ Progenitor
§ Others
§ Lineage
of Stem Cell
§
Adipose Tissue
§
Bone Marrow
§
Cord Blood
§
Others
§
Route of Administration
§
Intraarticular
§
Intracoronary
§
Intramuscular
§
Intramyocardial
§
Intrathecal
§
Intravenous
§
Surgical Implantations
§
Others
§
Therapeutic Area
§ Autoimmune
/ Inflammatory Disorder
§ Cardiovascular
Disorders
§ Metabolic
Disorder
§ Musculoskeletal
Disorders
§ Oncological
Disorders
§ Neurological
Disorders
§ Ophthalmic
Disorders
§ Others
§
End Users
§ Ambulatory
Surgery Centers
§ Hospitals
§ Specialty
Clinics
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
and Rest of the World
§ Transcripts of interviews held with the
following senior level representatives of stakeholder companies
§
William L Rust (Founder and Chief Executive Officer, Seraxis)
§
Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
§
Michel Revel (Co-Founder and Chief Scientist, Kadimastem)
and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
§
Kikuo Yasui (Director and Chief Operating Officer, Heartseed)
§
Gustav Steinhoff (Director and Chairman, Department of
Cardiac Surgery, University of Rostock)
§
Gilles Devillers (President, Bio Elpida)
§
Fiona Bellot (Business Development Manager, Roslin Cell
Therapies)
§
David Mckenna (Professor and American Red Cross Chair in
Transfusion Medicine, University of Minnesota)
§
Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
§
Mathilde Girard (Department Leader, Cell Therapy Innovation
and Development, YposKesi)
Key
companies covered in the report
§ Anterogen
§ Athersys
§ CHABiotech
§ Cytopeutics
§ Hope
Biosciences
§ Japan
Regenerative Medicine
§ Lineage
Cell Therapeutics
§ Orchard
Therapeutics
§ Osiris
Therapeutics
§ Pluristem
Therapeutics
§ Promithera
Biosciences
§ Regenexx
§ Stempeutics
Research
§ SCM
Life Sciences
§ TICEBA
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/
Other Recent Offerings
1.
Stem Cell Therapy
Contract Manufacturing Market, 2019-2030
2.
Antibody Drug Conjugates Market (5th Edition),
2019-2030
3.
Cell and Advanced
Therapies Supply Chain Management Market, 2019-2030: Focus on Technological
Solutions
4.
Global T-Cell (CAR-T,
TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com